Manulife (Manufacturers Life Insurance)
MRSN

Manulife (Manufacturers Life Insurance)’s Mersana Therapeutics MRSN Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-695
Closed -$5.98K – 2969
2025
Q1 		$5.98K Sell
695
-1,065
-61% -$16.4K ﹤0.01% 2892
2024
Q4 		$62.9K Sell
1,760
-19
-1% -$983 ﹤0.01% 2908
2024
Q3 		$84.1K Sell
1,779
-80
-4% -$3.53K ﹤0.01% 2908
2024
Q2 		$93.4K Buy
1,859
+174
+10% +$12.6K ﹤0.01% 2838
2024
Q1 		$189K Buy
1,685
+19
+1% +$1.89K ﹤0.01% 2614
2023
Q4 		$96.6K Hold
1,666
– – ﹤0.01% 2828
2023
Q3 		$52.9K Buy
1,666
+31
+2% +$1.47K ﹤0.01% 2938
2023
Q2 		$134K Buy
1,635
+211
+15% +$30.9K ﹤0.01% 2745
2023
Q1 		$146K Hold
1,424
– – ﹤0.01% 2658
2022
Q4 		$209K Buy
1,424
+11
+0.8% +$1.86K ﹤0.01% 2548
2022
Q3 		$239K Sell
1,413
-41
-3% -$6.66K ﹤0.01% 2459
2022
Q2 		$168K Buy
1,454
+200
+16% +$18.8K ﹤0.01% 2735
2022
Q1 		$125K Sell
1,254
-289
-19% -$33.8K ﹤0.01% 2919
2021
Q4 		$240 Buy
1,543
+21
+1% +$4.08K ﹤0.01% 2778
2021
Q3 		$359K Sell
1,522
-70
-4% -$20.4K ﹤0.01% 2534
2021
Q2 		$541K Buy
1,592
+370
+30% +$140K ﹤0.01% 2377
2021
Q1 		$494K Sell
1,222
-64
-5% -$31K ﹤0.01% 2289
2020
Q4 		$855K Buy
1,286
+60
+5% +$33.4K ﹤0.01% 1907
2020
Q3 		$571K Buy
1,226
+133
+12% +$67.2K ﹤0.01% 1939
2020
Q2 		$609K Buy
1,093
+135
+14% +$46.1K ﹤0.01% 1855
2020
Q1 		$140K Buy
958
+491
+105% +$85.8K ﹤0.01% 2469
2019
Q4 		$67K Buy
+467
New +$34.1K ﹤0.01% 2839
2019
Q3 		– Sell
-1,112
Closed -$113K – 2906
2019
Q2 		$113K Buy
+1,112
New +$131K ﹤0.01% 2865
2018
Q3 		– Sell
-434
Closed -$194K – 3525
2018
Q2 		$194K Buy
434
+54
+14% +$23.7K ﹤0.01% 3149
2018
Q1 		$149K Buy
380
+317
+503% +$125K ﹤0.01% 3235
2017
Q4 		$25K Buy
63
+43
+215% +$18.8K ﹤0.01% 3737
2017
Q3 		$9K Buy
+20
New +$7.88K ﹤0.01% 3871

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s MRSN Position: Q2 2025 in Review

Manulife (Manufacturers Life Insurance) sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 695 shares — an estimated $5.98K sold.

Manulife (Manufacturers Life Insurance) first reported a position in MRSN in Q3 2017 and held it in 27 quarters. The position peaked at $855K in Q4 2020. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • Manulife (Manufacturers Life Insurance) reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 695 Mersana Therapeutics shares in Q2 2025, an estimated $5.98K.
  • Manulife (Manufacturers Life Insurance) first reported a position in Mersana Therapeutics in Q3 2017 and held it in 27 quarters.
  • Manulife (Manufacturers Life Insurance)'s Mersana Therapeutics position peaked at $855K in Q4 2020.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2025, filed 14 Aug 2025.